
Amphastar Pharma (AMPH) Stock Forecast & Price Target
Amphastar Pharma (AMPH) Analyst Ratings
Bulls say
Amphastar Pharma is on track for future success as they continue to focus on the development and commercialization of new products in their pipeline. This is evident in their financial performance, with steady revenue growth in recent years and a strong presence in key markets like the United States and China. However, the company's success will depend heavily on their ability to successfully bring new products to market, which carries significant risks.
Bears say
Amphastar Pharma is facing significant pricing pressure and margin erosion due to higher rebates, channel mix, and 340B discounts on their flagship product Baqsimi, resulting in both top and bottom-line misses. This is compounded by competition in the glucagon and epinephrine markets and higher R&D costs, leading to a revised downward sales growth expectation. Additionally, the company is heavily influenced and controlled by two significant stockholders, adding further risk to the company's future performance.
This aggregate rating is based on analysts' research of Amphastar Pharma and is not a guaranteed prediction by Public.com or investment advice.
Amphastar Pharma (AMPH) Analyst Forecast & Price Prediction
Start investing in Amphastar Pharma (AMPH)
Order type
Buy in
Order amount
Est. shares
0 shares